Pages that link to "Q40048436"
Jump to navigation
Jump to search
The following pages link to Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist (Q40048436):
Displaying 50 items.
- Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics (Q26823789) (← links)
- Science gone translational: the OX40 agonist story (Q27022436) (← links)
- Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination (Q28068378) (← links)
- Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression (Q28730751) (← links)
- The use of immunotherapy in the treatment of melanoma (Q33593858) (← links)
- Control of immunity by the TNFR-related molecule OX40 (CD134) (Q33899607) (← links)
- The histone deacetylase inhibitor, LBH589, promotes the systemic cytokine and effector responses of adoptively transferred CD8+ T cells (Q33928765) (← links)
- Cell-extrinsic effects of tumor ER stress imprint myeloid dendritic cells and impair CD8⁺ T cell priming (Q34525738) (← links)
- Regulation of A1 by OX40 contributes to CD8(+) T cell survival and anti-tumor activity (Q34926132) (← links)
- The significance of OX40 and OX40L to T-cell biology and immune disease. (Q34979946) (← links)
- CD134 plus CD137 dual costimulation induces Eomesodermin in CD4 T cells to program cytotoxic Th1 differentiation (Q35228053) (← links)
- Beyond cancer vaccines: a reason for future optimism with immunomodulatory therapy (Q35294382) (← links)
- Immune checkpoint blockade and interferon-α in melanoma (Q35598991) (← links)
- Immunotherapy of cancer in 2012. (Q36243536) (← links)
- Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo (Q36433183) (← links)
- Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice. (Q36498243) (← links)
- OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival (Q36618831) (← links)
- Update on vaccine development for renal cell cancer (Q36989720) (← links)
- Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? (Q37114367) (← links)
- OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. (Q37273138) (← links)
- Integrating costimulatory agonists to optimize immune-based cancer therapies (Q37352989) (← links)
- The effect of aging on OX40 agonist-mediated cancer immunotherapy (Q37415424) (← links)
- OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells (Q37444300) (← links)
- The role of OX40-mediated co-stimulation in T-cell activation and survival (Q37524064) (← links)
- Cancer vaccine by fusions of dendritic and cancer cells (Q37698219) (← links)
- Adoptive T-cell immunotherapy of cancer using chimeric antigen receptor-grafted T cells (Q37725751) (← links)
- Immune regulatory antibodies: are they the next advance? (Q37778691) (← links)
- Signaling through OX40 enhances antitumor immunity (Q37809163) (← links)
- Using monoclonal antibodies to stimulate antitumor cellular immunity (Q37909430) (← links)
- Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation (Q38088635) (← links)
- OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal. (Q38374889) (← links)
- Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies (Q38806960) (← links)
- Immune Checkpoint Therapies in Prostate Cancer (Q38816839) (← links)
- Synergistic immunologic targets for the treatment of prostate cancer (Q38904873) (← links)
- Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy (Q39130451) (← links)
- Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity (Q39143599) (← links)
- Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer (Q39606073) (← links)
- Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice (Q39655881) (← links)
- How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy. (Q39664799) (← links)
- Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts. (Q41863325) (← links)
- CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion (Q43248975) (← links)
- Targeting macrophages in the tumour environment to enhance the efficacy of αOX40 therapy. (Q45957672) (← links)
- Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer (Q47155705) (← links)
- The Role of OX40 (CD134) in T-Cell Memory Generation (Q51039680) (← links)
- The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. (Q51955521) (← links)
- Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. (Q52594757) (← links)
- Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. (Q55216432) (← links)
- Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo (Q56795939) (← links)
- A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production (Q84454564) (← links)
- Immune checkpoint modulation enhances HIV-1 antibody induction (Q89790825) (← links)